Literature DB >> 27498384

Cholesterol efflux capacity of high-density lipoprotein correlates with survival and allograft vasculopathy in cardiac transplant recipients.

Ali Javaheri1, Maria Molina2, Payman Zamani2, Amrith Rodrigues2, Eric Novak3, Susan Chambers2, Patricia Stutman2, Wilhelmina Maslanek2, Mary Williams2, Scott M Lilly4, Peter Heeger5, Mohamed H Sayegh6, Anil Chandraker7, David M Briscoe8, Kevin P Daly8, Randall Starling9, David Ikle10, Jason Christie2, J Eduardo Rame2, Lee R Goldberg2, Jeffrey Billheimer2, Daniel J Rader2.   

Abstract

BACKGROUND: Cardiac allograft vasculopathy (CAV) is a major cause of mortality after cardiac transplantation. High-density lipoprotein (HDL) cholesterol efflux capacity (CEC) is inversely associated with coronary artery disease. In 2 independent studies, we tested the hypothesis that reduced CEC is associated with mortality and disease progression in CAV.
METHODS: We tested the relationship between CEC and survival in a cohort of patients with CAV (n = 35). To determine whether reduced CEC is associated with CAV progression, we utilized samples from the Clinical Trials in Organ Transplantation 05 (CTOT05) study to determine the association between CEC and CAV progression and status at 1 year (n = 81), as assessed by average change in maximal intimal thickness (MIT) on intravascular ultrasound.
RESULTS: Multivariable Cox proportional hazard models demonstrated that higher levels of CEC were associated with improved survival (hazard ratio 0.26, 95% confidence interval 0.11 to 0.63) per standard deviation CEC, p = 0.002). Patients who developed CAV had reduced CEC at baseline and 1-year post-transplant. We observed a significant association between pre-transplant CEC and the average change in MIT, particularly among patients who developed CAV at 1 year (β = -0.59, p = 0.02, R2 = 0.35).
CONCLUSION: Reduced CEC is associated with disease progression and mortality in CAV patients. These findings suggest the hypothesis that interventions to increase CEC may be useful in cardiac transplant patients for prevention or treatment of CAV.
Copyright © 2016 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiac allograft vasculopathy; cholesterol efflux capacity; high-density lipoprotein; survival; transplantation

Mesh:

Substances:

Year:  2016        PMID: 27498384      PMCID: PMC5107129          DOI: 10.1016/j.healun.2016.06.022

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  37 in total

Review 1.  Selection of cardiac transplantation candidates in 2010.

Authors:  Donna Mancini; Katherine Lietz
Journal:  Circulation       Date:  2010-07-13       Impact factor: 29.690

Review 2.  The prognostic significance of intimal proliferation in cardiac allograft vasculopathy: a paradigm shift.

Authors:  M R Mehra; H O Ventura; D D Stapleton; F W Smart
Journal:  J Heart Lung Transplant       Date:  1995 Nov-Dec       Impact factor: 10.247

3.  The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report--2012.

Authors:  Josef Stehlik; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Jason D Christie; Anne I Dipchand; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; Marshall I Hertz
Journal:  J Heart Lung Transplant       Date:  2012-10       Impact factor: 10.247

4.  Reconstituted high-density lipoprotein therapies: a cause for optimism.

Authors:  Ali Javaheri; Daniel M Kolansky; Marina Cuchel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-09       Impact factor: 8.311

5.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

6.  Statin use and risks of death or fatal rejection in the Heart Transplant Lipid Registry.

Authors:  Audrey H Wu; Christie M Ballantyne; Beth C Short; Guillermo Torre-Amione; James B Young; Hector O Ventura; Howard J Eisen; Branislav Radovancevic; Barry K Rayburn; Kathleen D Lake; Clyde W Yancy; David O Taylor; Mandeep R Mehra; Spencer H Kubo; Daniel P Fishbein; Xue-Qiao Zhao; Kevin D O'Brien
Journal:  Am J Cardiol       Date:  2005-02-01       Impact factor: 2.778

7.  In vivo comparison between cardiac allograft vasculopathy and native atherosclerosis using near-infrared spectroscopy and intravascular ultrasound.

Authors:  Bo Zheng; Akiko Maehara; Gary S Mintz; Tamim M Nazif; Yarden Waksman; Fuyu Qiu; Luz Jaquez; LeRoy E Rabbani; Mark A Apfelbaum; Ziad A Ali; Kate Dalton; Ke Xu; Charles C Marboe; Donna M Mancini; Giora Weisz
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2015-02-25       Impact factor: 6.875

8.  Cyclosporine A and PSC833 inhibit ABCA1 function via direct binding.

Authors:  Kohjiro Nagao; Minami Maeda; Noralyn B Mañucat; Kazumitsu Ueda
Journal:  Biochim Biophys Acta       Date:  2012-11-12

9.  Inflammation/oxidation in chronic rejection: apolipoprotein a-i mimetic peptide reduces chronic rejection of transplanted hearts.

Authors:  George R Hsieh; Gabriel T Schnickel; Consuelo Garcia; Ali Shefizadeh; Michael C Fishbein; Abbas Ardehali
Journal:  Transplantation       Date:  2007-07-27       Impact factor: 4.939

10.  Elevated HDL cholesterol is functionally ineffective in cardiac transplant recipients: evidence for impaired reverse cholesterol transport.

Authors:  Dmitri Sviridov; Jaye Chin-Dusting; Paul Nestel; Bronwyn Kingwell; Anh Hoang; Beata Olchawa; Jennifer Starr; Anthony Dart
Journal:  Transplantation       Date:  2006-02-15       Impact factor: 4.939

View more
  7 in total

1.  Cholesterol efflux capacity, HDL cholesterol, and risk of coronary heart disease: a nested case-control study in men.

Authors:  Leah E Cahill; Frank M Sacks; Eric B Rimm; Majken K Jensen
Journal:  J Lipid Res       Date:  2019-05-29       Impact factor: 5.922

Review 2.  Cholesterol efflux in the transplant patient.

Authors:  Sangita Sudharshan; Ali Javaheri
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2018-04       Impact factor: 3.243

3.  Hyperlipidemia and Allograft Rejection.

Authors:  Jessamyn Bagley; Linus Williams; Michael Hyde; Christian Rosa Birriel; John Iacomini
Journal:  Curr Transplant Rep       Date:  2019-02-26

Review 4.  High-density lipoprotein cholesterol efflux capacity is inversely associated with cardiovascular risk: a systematic review and meta-analysis.

Authors:  Chengfeng Qiu; Xiang Zhao; Quan Zhou; Zhen Zhang
Journal:  Lipids Health Dis       Date:  2017-11-10       Impact factor: 3.876

5.  Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis.

Authors:  Jane J Lee; Gerald Chi; Clara Fitzgerald; Syed Hassan A Kazmi; Arzu Kalayci; Serge Korjian; Danielle Duffy; Alka Shaunik; Bronwyn Kingwell; Robert W Yeh; Deepak L Bhatt; C Michael Gibson
Journal:  Front Cardiovasc Med       Date:  2021-12-13

Review 6.  HDL Composition, Heart Failure, and Its Comorbidities.

Authors:  Ahmed Diab; Carla Valenzuela Ripoll; Zhen Guo; Ali Javaheri
Journal:  Front Cardiovasc Med       Date:  2022-03-08

Review 7.  High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives.

Authors:  Maria Pia Adorni; Nicoletta Ronda; Franco Bernini; Francesca Zimetti
Journal:  Cells       Date:  2021-03-05       Impact factor: 7.666

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.